Selected article for: "antiviral drug and lopinavir ritonavir arbidol oseltamivir"
Author: Xudan Chen; Yang Zhang; Baoyi Zhu; Jianwen Zeng; Wenxin Hong; Xi He; Jingfeng Chen; Haipeng Zheng; Shuang Qiu; Ying Deng; Juliana Chan; Jian Wang
Title: Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study
  • Document date: 2020_4_14
    • ID: 9j4ese89_30
    Snippet: Arbidol is an antiviral drug approved in Russia and China for treating influenza. It acts against influenza A and B by inhibiting viral fusion with cellular membrane and blocking the virus entry into host cells [23] . In a retrospective cohort study, arbidol accelerated the clearance of viral RNA in patients with COVID-19 compared to empirical treatment [14] . In China, it has been recommended as one of the antiviral drugs for COVID-19 [11] . Ose.....
    Document: Arbidol is an antiviral drug approved in Russia and China for treating influenza. It acts against influenza A and B by inhibiting viral fusion with cellular membrane and blocking the virus entry into host cells [23] . In a retrospective cohort study, arbidol accelerated the clearance of viral RNA in patients with COVID-19 compared to empirical treatment [14] . In China, it has been recommended as one of the antiviral drugs for COVID-19 [11] . Oseltamivir is another drug approved for the treatment of influenza A and B [24], and has been used in some patients with COVID-19 [3, 7] . In this study, neither arbidol nor oseltamivir exhibited positive effects on the viral RNA clearance of COVID-19. Further, the combination of arbidol with another antiviral drug, oseltamivir or lopinavir/ritonavir, tended to delay clearance of viral RNA. All rights reserved. No reuse allowed without permission.

    Search related documents:
    Co phrase search for related documents
    • antiviral drug and cellular membrane: 1
    • antiviral drug and cohort study: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • antiviral drug and empirical treatment: 1, 2
    • antiviral drug and host cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral drug and influenza treat: 1, 2, 3, 4, 5, 6, 7
    • antiviral drug and lopinavir ritonavir oseltamivir: 1, 2
    • antiviral drug and lopinavir ritonavir oseltamivir antiviral drug: 1
    • antiviral drug and oseltamivir arbidol: 1, 2
    • arbidol combination and cohort study: 1, 2, 3
    • arbidol combination and host cell: 1
    • arbidol combination and lopinavir ritonavir oseltamivir: 1
    • arbidol combination and oseltamivir arbidol: 1, 2
    • cellular membrane and host cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cellular membrane viral fusion and host cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • cohort study and empirical treatment: 1, 2, 3, 4, 5, 6, 7
    • cohort study and host cell: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • cohort study and influenza treat: 1
    • cohort study and lopinavir ritonavir oseltamivir: 1, 2, 3
    • empirical treatment and host cell: 1